MeSH term | MeSH ID | Detail |
---|---|---|
Ileus | D045823 | 3 associated lipids |
Rectal Diseases | D012002 | 1 associated lipids |
Angiolymphoid Hyperplasia with Eosinophilia | D000796 | 1 associated lipids |
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Damotte D et al. | Morphologic features of large bowel biopsies in combined small and large bowel transplantations could predict clinical rejection. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083252 |
Kandaswamy R et al. | Vascular graft thrombosis after pancreas transplantation: comparison of the FK 506 and cyclosporine eras. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083254 |
Humar A et al. | Surgical complications requiring early relaparotomy after pancreas transplantation: comparison of the cyclosporine and FK 506 eras. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083256 |
Kaufman DB et al. | Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083261 |
Stratta RJ | Optimal immunosuppression in pancreas transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083263 |
Rastellini C et al. | Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083278 |
Rao AS et al. | Immune modulation in organ allograft recipients by single or multiple donor bone marrow infusions. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083302 |
Kaibori M et al. | Inhibition of iNOS induction by FK506, but not by cyclosporine, in rat hepatocytes. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083347 |
Terakura M et al. | Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083380 |
Song Z et al. | FK 506 prevents islet xenograft rejection: a study in the pig-to-rat model. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083437 |
Navia MA | Rational design of new immunosuppressive drugs. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083489 |
McAlister VC et al. | Oral delivery of liposomal tacrolimus: increased efficacy and reduced toxicity. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083495 |
Klupp J et al. | Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083497 |
Yang HC et al. | Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation--1-year follow-up of a prospective, randomized clinical trial. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083501 |
Steinmueller T et al. | The effect of cyclosporine vs FK 506 on glucose metabolism. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083504 |
Shapiro R et al. | A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083507 |
Opelz G | Immunosuppression with FK 506 does not improve kidney graft survival. Collaborative Transplant Study. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083513 |
Kokado Y et al. | Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083515 |
Zuckermann A et al. | Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083518 |
Zanker B et al. | Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083521 |